Improdia’s mission is to optimize personalized treatments of patients suffering from pathologies characterized by chronic inflammation. Improdia is developing a simple, rapid, reliable and non-invasive blood test for the evaluation of the individuals’ immune status and inflammatory conditions based on revolutionary biomarkers, which sense the patients’ immune system function.

Improdia™ had discovered and patented revolutionary biomarkers and desigend a flow cytometry-based prognostic, diagnostic kit for evaluating patients’ immune system function.

Clinical results in diabetic patients demonstrate the advantages of Improdia’s novel biomarkers compared with the golden standard CRP and Hba1c tests.

In 2010, the total global market for biomarkers was estimated $13.5 billion and is expected to grow to nearly $33.3 billion by the end of 2015 at a 5-year compound annual growth rate of 19.8%.

Sustained exposure to bacterial antigenNature Immunology 4:957-964 (2003).

TCR zeta-chain down regulationNature Reviews Immunology 4:675-687 (2004).

TCR zeta down-regulation under chronic inflammationThe Journal of Immunology, 177: 4763-4772 (2006).

Site Designed by Noa Goldfarb | Developed by Or Sela